P. R. Herzig & Company acquired a new stake in shares of Novo Nordisk A/S (NYSE:NVO) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 7,800 shares of the company’s stock, valued at approximately $453,000.

A number of other large investors have also modified their holdings of the stock. Beacon Capital Management acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at about $0. Park National acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at about $231,000. Filament acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at about $305,000. Eagle Asset Management raised its stake in shares of Novo Nordisk A/S by 99.8% in the third quarter. Eagle Asset Management now owns 9,276 shares of the company’s stock valued at $502,000 after buying an additional 4,633 shares during the last quarter. Finally, Atria Investments raised its stake in shares of Novo Nordisk A/S by 10.7% in the fourth quarter. Atria Investments now owns 13,453 shares of the company’s stock valued at $737,000 after buying an additional 1,300 shares during the last quarter.

Novo Nordisk A/S (NYSE:NVO) opened at 54.74 on Monday. Novo Nordisk A/S has a 52 week low of $41.87 and a 52 week high of $60.34. The company has a 50-day moving average of $56.24 and a 200-day moving average of $55.90. The firm has a market cap of $140.46 billion and a price-to-earnings ratio of 29.43.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Thursday, October 29th. The company reported $0.48 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.47 by $0.02. Equities research analysts forecast that Novo Nordisk A/S will post $1.99 earnings per share for the current fiscal year.

NVO has been the topic of several recent research reports. Zacks Investment Research lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, October 27th. Vetr upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating and set a $64.00 price objective on the stock in a research note on Thursday, January 7th. Three investment analysts have rated the stock with a sell rating, four have given a hold rating, one has assigned a buy rating and two have given a strong buy rating to the stock. Novo Nordisk A/S has an average rating of “Hold” and a consensus target price of $60.67.

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It has a range of diabetes product portfolio, including a portfolio of modern insulins as well as a human once-daily GLP-1 analog. It operates in two segments: diabetes care and biopharmaceuticals. The Company’s diabetes care segment covers insulins, GLP-1, other protein-related products (NYSE:NVO), oral anti-diabetic drugs and obesity. Its biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy. The primary production facilities owned by the Company are located at a number of sites in Denmark, and internationally in the United States, France, China and Brazil.

12 Month Chart for NYSE:NVO

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.